Medtech bleeds corporate venture cash
Overall venture investment in the sector remains steady, but the big strategics back off.
Philips draws a line under its sleep nightmare
The group has finally revalued its troubled sleep franchise. So what now?
Ember burns bright for Angle
A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.
TCT 2022 – Otsuka’s renal denervation system shines
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
TCT 2022 – Edwards tries to Clasp an opportunity
The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?
Esmo 2022 – Galleri’s real-world exhibition disappoints
Grail finds the path for its liquid biopsy less clear than it might have hoped.
Medtech takes on pain
Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.
